Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.54 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 15/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886747 | 0.94 | CAPN1 (0.49) | DCAF1CTSVCTSLCTSSCTSK | |
| SCHEMBL22885939 | 0.92 | DCAF1 (0.50) | DCAF1CTSVCTSLCTSSCTSK | |
| SCHEMBL23268990 | 0.91 | CAPN1 (0.59) | DCAF1CTSSCAPN1 | |
| SCHEMBL20028632 | 0.91 | CAPN1 (0.59) | DCAF1CTSSCAPN1 | |
| SCHEMBL22886415 | 0.90 | DCAF1 (0.52) | DCAF1CTSVCTSLCTSSCTSK | |
| SCHEMBL22886629 | 0.90 | DCAF1 (0.50) | DCAF1CTSVCTSLCTSSCTSK | |
| SCHEMBL22886498 | 0.88 | L3MBTL1 (0.46) | DCAF1CTSVCTSLCTSSCTSK | |
| SCHEMBL22886521 | 0.87 | CAPN1 (0.48) | CAPN1 | |
| SCHEMBL21410955 | 0.87 | CTSL (0.44) | DCAF1CTSVCTSLCTSSCTSK | |
| SCHEMBL29961323 | 0.87 | CTSL (0.44) | DCAF1CTSVCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | DCAF1 2355/4885CTSV 159/4885CTSL 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.